• Novel Approach Measures Tau Changes That Correlate With Dementia Stage

    Bio-IT World | The chemistry of tau protein in the brains of Alzheimer’s patients looks different at early and later stages of the disease, suggesting it could serve as a biomarker of disease progression. Although dementia researchers have historically focused almost entirely on abnormal accumulations of beta-amyloid, tau correlates better with cognitive decline and thus understanding its chemistry is key, says Judith Steen, Ph.D., associate professor of neurology at Harvard Medical School.

    Feb 18, 2021

  • Using Chromatography Data Systems to Drive Control, Compliance, Productivity

    Bio-IT World | In the modern-day analytical laboratory, chromatography and mass spectrometry (MS) are increasingly seen working side by side. These complementary techniques provide powerful insight into the quantity, size, and structure of a wide range of analytes. But despite the combined power of these systems, the practical instrumentation, data management and reporting are often anything but connected.

    Feb 17, 2021

  • Data Wrangling: Priming UK Biobank Data to Drive Discovery

    Bio-IT World | TRENDS FROM THE TRENCHES | Biopharma’s new superheroes are the data wranglers who have equal access to the rich data sets available through the UK Biobank project. In pharma and biotech, these professionals work at the next level of data management going beyond traditional and straightforward data extraction, transformation, and loading processes to bring knowledge from the data.

    Feb 16, 2021

  • Hallmarks of a Super-Spreader, Spike Pattern of the 1928 Pandemic, Airborne Transmission Model: COVID-19 Updates

    Bio-IT World | New machine learning framework estimates asymptomatic cases, helium microscope used to visualize SARS CoV-2, SARS CoV-2 mutations develop in single patient, and new vaccine platforms. Plus: clinicians at UCI Health develop successful system for monoclonal antibody delivery, New Yorkers are responding more favorably to the new COVID-19 vaccine, and old drugs may be repurposed as COVID-19 treatments.

    Feb 12, 2021

  • A Deep Dive On mRNA Vaccines

    Bio-IT World | Messenger RNA (mRNA) vaccines were the focus of a symposium on COVID-19 vaccines held during last week’s COVID-19 and Cancer virtual meeting of the American Association for Cancer Research. To date, only two vaccines have received Emergency Use Authorization by the U.S. Food and Drug Administration and both are mRNA vaccines—one developed by Moderna and the other by Pfizer and BioNTech.

    Feb 11, 2021

  • Sema4 Announces Merger With CM Life Sciences

    Bio-IT World | Sema4 announced its planned merger with CM Life Sciences today. The transaction combines Sema4’s leading AI- and machine learning-powered integrated genomic and clinical open-architecture data platform, with CM Life Sciences, a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP. The transaction is expected to provide up to $793 million in immediate cash proceeds.

    Feb 10, 2021

  • The Future of Our Blood Supply Chain is Digital

    Bio-IT World | The impact of the COVID-19 pandemic on our nation’s blood supply was not very apparent in public discussion. And yet the radical shifts in the demand for blood products, and the availability thereof, should be studied and analyzed to improve the robustness and resilience of our blood supply.

    Feb 10, 2021

  • GenomePaint: Interactive Visualization of the Genome

    Bio-IT World | The computational biology team at St. Jude has published the latest on GenomePaint, one of the visualization features in the St. Jude Cloud platform, in the January issue of Cancer Cell.

    Feb 9, 2021

  • Heparin Inhibits SARS-CoV-2, How Mutations Escape Immune Response, Retraining Generic Antibodies: COVID-19 Updates

    Bio-IT World | Genetic sequence deletions help SARS-CoV-2 escape antibodies, molecular behavior of COVID-19 drugs, and the latest COVID-19 forecasts include two new variants. Plus: N439K variant shows two-fold increase in binding affinity and heparin inhibits SARS-CoV-2 spike protein, could be repurposed.

    Feb 5, 2021

  • AI-Based Approach Crunches Real-World Data To Emulate Clinical Trials

    Bio-IT World | A computer scientist at The Ohio State University (OSU) recently demonstrated the potential of artificial intelligence to crunch real-world data and emulate randomized clinical trials, speeding the pace of drug repurposing.

    Feb 4, 2021